Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Nutr Cancer ; 75(9): 1743-1751, 2023.
Article in English | MEDLINE | ID: mdl-37553951

ABSTRACT

Preoperative nutritional status is an important and modifiable risk factor of a patient's recovery and outcome after radical cystectomy. There are multiple malnutrition screening tools and treatment options. In this review, we discuss the best indicators of this condition and how to optimize nutrition status prior to radical cystectomy.


Subject(s)
Enhanced Recovery After Surgery , Urinary Bladder Neoplasms , Humans , Cystectomy/adverse effects , Urinary Bladder Neoplasms/surgery , Nutritional Status , Postoperative Complications/etiology , Postoperative Complications/prevention & control
2.
Curr Oncol Rep ; 24(4): 399-414, 2022 04.
Article in English | MEDLINE | ID: mdl-35141856

ABSTRACT

PURPOSE OF REVIEW: For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS: The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immune-related adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients.


Subject(s)
Neoplasms , Oncolytic Virotherapy , Physicians , Humans , Immune Checkpoint Inhibitors , Immunologic Factors , Immunotherapy/adverse effects , Neoplasms/pathology
3.
World J Urol ; 39(2): 433-441, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32318858

ABSTRACT

BACKGROUND: Epidural anesthesia has been associated with a decrease in cardiopulmonary complications and a decrease in blood loss in orthopedic procedures. Its influence on the outcomes of patients receiving radical cystectomies is unknown. We aim to use the large national database from the National Surgical Quality Improvement Project (NSQIP) to examine whether postoperative complications may be affected by the use of epidural anesthesia during radical cystectomy. METHODS: Data were collected from the 2014-2016 participant user files of the NSQIP database. Patients receiving radical cystectomy were identified by CPT code and further stratified by anesthesia type. Demographics, length of stay, and 30-day complications including death were collected and analyzed using univariable and multivariable analysis. RESULTS: A total of 6448 patients met the inclusion criteria for analysis. Between 2014 and 2016, 5064 patients received general anesthesia only (GA) and 1384 patients received general and epidural anesthesia (GEA). Statistical analysis showed an overall increase in major complications (17.8% vs 18.5%) in the GEA group (p = 0.0046). Subgroup analysis showed major complications to be more likely in patients older than 75 years receiving GEA instead of GA (p = 0.0301). CONCLUSIONS: Elderly patients (age > 75) undergoing radical cystectomy may experience more major complications with the use of epidural anesthesia. This may be due to end-organ effects from the hemodynamic changes of epidural anesthesia which are poorly tolerated in the elderly population. Further single intervention epidural studies need to be performed to isolate the effects of epidural anesthesia on individual surgical procedures.


Subject(s)
Anesthesia, Epidural/adverse effects , Cystectomy , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Aged , Cystectomy/methods , Databases, Factual , Female , Humans , Male , Middle Aged , Quality Improvement , United States
4.
Anesth Analg ; 133(3): 676-689, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34100781

ABSTRACT

Preclinical and clinical studies have sought to better understand the effect of anesthetic agents, both volatile and intravenous, and perioperative adjuvant medications on immune function. The immune system has evolved to incorporate both innate and adaptive components, which are delicately interwoven and essential for host defense from pathogens and malignancy. This review summarizes the complex and nuanced relationship that exists between each anesthetic agent or perioperative adjuvant medication studied and innate and adaptive immune function with resultant clinical implications. The most commonly used anesthetic agents were chosen for review including volatile agents (sevoflurane, isoflurane, desflurane, and halothane), intravenous agents (propofol, ketamine, etomidate, and dexmedetomidine), and perioperative adjuvant medications (benzodiazepines, opioids, nonsteroidal anti-inflammatory drugs [NSAIDs], and local anesthetic agents). Patients who undergo surgery experience varying combinations of the aforementioned anesthetic agents and adjuncts, depending on the type of surgery and their comorbidities. Each has unique effects on immunity, which may be more or less ideal depending on the clinical situation. Further study is needed to better understand the clinical effects of these relationships so that patient-specific strategies can be developed to improve surgical outcomes.


Subject(s)
Adaptive Immunity/drug effects , Adjuvants, Anesthesia/therapeutic use , Anesthesia, Inhalation , Anesthesia, Intravenous , Anesthetics, Inhalation/therapeutic use , Anesthetics, Intravenous/therapeutic use , Immune System/drug effects , Immunity, Innate/drug effects , Perioperative Care , Adjuvants, Anesthesia/adverse effects , Anesthesia, Inhalation/adverse effects , Anesthesia, Intravenous/adverse effects , Anesthetics, Inhalation/adverse effects , Anesthetics, Intravenous/adverse effects , Animals , Humans , Immune System/immunology , Immune System/physiopathology , Perioperative Care/adverse effects , Postoperative Complications/chemically induced , Postoperative Complications/immunology , Risk Factors
5.
Cancer Control ; 27(1): 1073274820965575, 2020.
Article in English | MEDLINE | ID: mdl-33070618

ABSTRACT

The surgical stress and inflammatory response and volatile anesthetic agents have been shown to promote tumor metastasis in animal and in-vitro studies. Regional neuraxial anesthesia protects against these effects by decreasing the surgical stress and inflammatory response and associated changes in immune function in animals. However, evidence of a similar effect in humans remains equivocal due to the high variability and retrospective nature of clinical studies and difficulty in directly comparing regional versus general anesthesia in humans. We propose a theoretical framework to address the question of regional anesthesia as protective against metastasis.This theoretical construct views the immune system, circulating tumor cells, micrometastases, and inflammatory mediators as distinct populations in a highly connected system. In ecological theory, highly connected populations demonstrate more resilience to local perturbations but are prone to system-wide shifts compared with their poorly connected counterparts. Neuraxial anesthesia transforms the otherwise system-wide perturbations of the surgical stress and inflammatory response and volatile anesthesia into a comparatively local perturbation to which the system is more resilient. We propose this framework for experimental and mathematical models to help determine the impact of anesthetic choice on recurrence and metastasis and create therapeutic strategies to improve cancer outcomes after surgery.


Subject(s)
Anesthesia, General/statistics & numerical data , Inflammation/prevention & control , Models, Theoretical , Neoplasm Recurrence, Local/prevention & control , Neoplasms/surgery , Anesthesia, Conduction/methods , Anesthesia, Conduction/statistics & numerical data , Anesthesia, General/adverse effects , Animals , Humans , Inflammation/etiology , Neoplasm Metastasis , Neoplasm Recurrence, Local/etiology , Neoplasms/epidemiology , Neoplasms/pathology
6.
World J Surg ; 43(3): 839-845, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30456482

ABSTRACT

BACKGROUND: Enhanced recovery after surgery (ERAS) protocols have been shown to improve surgical, anesthetic, and economic outcomes in intermediate-to-high-risk surgeries. Its influence on length of stay and cost of low-risk surgeries has yet to be robustly studied. As value-based patient care comes to the forefront of anesthesiology research, the focus shifts to strategies that maintain quality while effectively containing cost. METHODS: In July 2016, we implemented an ERAS for mastectomy protocol consisting of limiting fasting state, preoperative multimodal analgesia, and pectoralis I and II blocks. After 1 year, patient records were retrospectively reviewed for length of stay, opioid consumption, pain scores, and hospital charges. RESULTS: Implementation of an ERAS protocol for mastectomies led to a decrease in opioid consumption, and statistically significant decrease in length of stay (1.19 vs. 1.44, p = 0.01). No significant change in hospital charges was observed ($25,787 vs. $25,863, p = 0.97); however, the variance of charges was significantly decreased (6.8 × 107 vs. 1.5 × 108, p = 0.002). The decrease in length of stay translated to an extra 100 hospital bed days which can provide up to an additional $2,100,000 in gross patient service revenue from additional mastectomy volume. CONCLUSION: ERAS protocols for mastectomies may prove beneficial by allowing growing hospitals to increase bed capacity and consequently surgical volume. Despite no change in hospital charges, we predict a potential increase in gross patient service revenue of $2.1 million due to saved hospital bed days.


Subject(s)
Breast Neoplasms/surgery , Length of Stay/economics , Mastectomy/economics , Perioperative Care/methods , Aged , Analgesics, Opioid/therapeutic use , Breast Neoplasms, Male/surgery , Female , Hospital Charges , Humans , Male , Mastectomy/adverse effects , Middle Aged , Pain Management/methods , Pain, Postoperative/drug therapy , Pain, Postoperative/etiology , Retrospective Studies
8.
Cureus ; 16(2): e53914, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38343706

ABSTRACT

Cardiovascular complications are a major cause of morbidity and mortality after surgery, necessitating adequate and thorough preoperative risk stratification and screening. Several technological advances in cardiac remote monitoring have improved the assessment and diagnosis of cardiovascular disease in patients before and after surgery. These devices perform measurements of physiological function, including vital signs, and more advanced functions, such as electrocardiograms and heart sound recordings. Some of the currently available devices include Fitbit® (Google LLC, Mountain View, CA, USA), BodyGuardian® (Preventive Inc., Rochester, MN, USA), ZephyrTM Performance Systems (Zephyr Inc., Annapolis, MD, USA), Sensium® (The Surgical Company, Amersfoort, UT, The Netherlands), KardiaMobile® (AliveCor, Mountain View, CA, USA), Coala® Heart Monitor (Coala Life Inc., Uppsala, Sweden), Smartex® Wearable Wellness System (Smartex, Porto, LX, Portugal), Eko® CORE and DUO (Eko Health, Emeryville, CA, USA), and TytoCareTM (TytoCare Ltd., New York, USA). Early studies have applied these devices to asymptomatic individuals and those with known cardiovascular disease with good sensitivity and specificity for electrophysiologic diagnosis. These devices carry several technical and other limitations, somewhat restricting the generalization of their use to all patients. However, information gathered from these devices can further guide anesthetic technique, operative timing, and postoperative follow-up, among other variables. As telehealth becomes more prevalent and comprehensive, it is paramount for the perioperative physician to be familiar with the available cardiac remote monitoring technologies.

9.
Clin Pract ; 14(3): 906-914, 2024 May 17.
Article in English | MEDLINE | ID: mdl-38804403

ABSTRACT

The Revised Cardiac Risk Index (RCRI) and the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) preoperative risk assessment tools are the most widely used methods for quantifying the risk of major negative perioperative cardiac outcomes that a patient may face during and after noncardiac surgery. However, these tools were created to include as wide a range of surgical factors as possible; thus, some predictive accuracy is sacrificed when it comes to certain surgical subpopulations. In this review, we explore the various surgical oncology patient populations for whom these assessment tools can be reliably applied and for whom they demonstrate poor reliability.

10.
PLoS One ; 18(10): e0292492, 2023.
Article in English | MEDLINE | ID: mdl-37816047

ABSTRACT

INTRODUCTION: Volatile and intravenous anesthetics may worsen oncologic outcomes in basic science animal models. These effects may be related to suppressed innate and adaptive immunity, decreased immunosurveillance, and disrupted cellular signaling. We hypothesized that anesthetics would promote lung tumor growth via altered immune function in a murine model and tested this using an immunological control group of immunodeficient mice. METHODS: Lewis lung carcinoma cells were injected via tail vein into C57BL/6 immunocompetent and NSG immunodeficient mice during exposure to isoflurane and ketamine versus controls without anesthesia. Mice were imaged on days 0, 3, 10, and 14 post-tumor cell injection. On day 14, mice were euthanized and organs fixed for metastasis quantification and immunohistochemistry staining. We compared growth of tumors measured from bioluminescent imaging and tumor metastasis in ex vivo bioluminescent imaging of lung and liver. RESULTS: Metastases were significantly greater for immunocompromised NSG mice than immunocompetent C57BL/6 mice over the 14-day experiment (partial η2 = 0.67, 95% CI = 0.54, 0.76). Among immunocompetent mice, metastases were greatest for mice receiving ketamine, intermediate for those receiving isoflurane, and least for control mice (partial η2 = 0.88, 95% CI = 0.82, 0.91). In immunocompetent mice, significantly decreased T lymphocyte (partial η2 = 0.83, 95% CI = 0.29, 0.93) and monocyte (partial η2 = 0.90, 95% CI = 0.52, 0.96) infiltration was observed in anesthetic-treated mice versus controls. CONCLUSIONS: The immune system appears central to the pro-metastatic effects of isoflurane and ketamine in a murine model, with decreased T lymphocytes and monocytes likely playing a role.


Subject(s)
Anesthetics, Inhalation , Anesthetics , Isoflurane , Ketamine , Mice , Animals , Isoflurane/adverse effects , Ketamine/pharmacology , Disease Models, Animal , Xylazine/pharmacology , Mice, Inbred C57BL , Anesthetics/pharmacology , Immunity , Anesthetics, Inhalation/adverse effects
11.
Brachytherapy ; 19(3): 328-336, 2020.
Article in English | MEDLINE | ID: mdl-32122807

ABSTRACT

Gynecologic brachytherapy procedures require targeted procedural and anesthetic needs including optimization of intra- and post-procedure analgesia, low rate of complications, and appropriate and timely transitions of care. It is uncertain whether neuraxial or general anesthesia is superior for these and other anesthetic outcomes. After a targeted search of the recent literature for anesthesia and analgesia studies for gynecologic brachytherapy, twenty studies were identified and appraised for potential review. Meta-analysis showed a decreased frequency in rescue analgesic administration in patients who underwent neuraxial anesthesia compared with general anesthesia for the procedure and literature review showed a comparable rate of anesthesia-related complications. Neuraxial anesthesia may be considered for gynecologic brachytherapy because of improved pain control, decreased opioid consumption, and similar rate of anesthesia complications.


Subject(s)
Analgesics/therapeutic use , Anesthesia/methods , Brachytherapy , Genital Neoplasms, Female/radiotherapy , Pain/prevention & control , Analgesics, Opioid/therapeutic use , Anesthesia/adverse effects , Anesthesia, Epidural/adverse effects , Anesthesia, General/adverse effects , Anesthesia, Spinal/adverse effects , Brachytherapy/adverse effects , Brachytherapy/methods , Female , Humans , Pain/etiology
12.
A A Pract ; 14(2): 63-66, 2020 Jan 15.
Article in English | MEDLINE | ID: mdl-31703004

ABSTRACT

Despite an abundance of evidence, routine perioperative antifibrinolytics have been avoided in oncology patients due to concern of thrombosis when given to patients with a preexisting hypercoagulable state. We present a retrospective review of 104 patients with an oncologic diagnosis who received intraoperative tranexamic acid during orthopedic surgery. Overall, complication rates were low, including deep vein thrombosis (1.0%), pulmonary embolism (4.8%), stroke (0%), and myocardial infarction (0%). This preliminary evidence shows that antifibrinolytics such as tranexamic acid may be considered perioperatively in oncology patients without increased risk of thromboembolic events; however, further prospective trials are encouraged.


Subject(s)
Antifibrinolytic Agents/administration & dosage , Blood Loss, Surgical/prevention & control , Neoplasms/surgery , Thromboembolism/epidemiology , Tranexamic Acid/administration & dosage , Adult , Aged , Antifibrinolytic Agents/adverse effects , Female , Humans , Incidence , Intraoperative Care , Male , Middle Aged , Orthopedic Procedures/adverse effects , Tranexamic Acid/adverse effects , Treatment Outcome
13.
Nutr Clin Pract ; 35(2): 246-253, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31637778

ABSTRACT

Preoperative carbohydrate loading is a contemporary element of the enhanced recovery after surgery (ERAS) paradigm. In addition to intraoperative surgical and anesthetic modifications and postoperative care practices, preoperative optimization is essential to good postsurgical outcomes. What was long held as dogma, a period of prolonged fasting prior to the administration of anesthesia, was later re-examined and challenged. Along with the proposed physiologic effects of decreasing the surgical stress response and insulin resistance, preoperative carbohydrate loading was also demonstrated to improve patient satisfaction and well-being, without an increase in perioperative complications. The benefits are most strongly observed in abdominal and cardiac surgery patients, but there has also been data which support its use in other specialties and surgeries. Barriers to the adoption of perioperative carbohydrate loading are few, but importantly include overcoming the inertia to modify older and more restrictive fasting guidelines and achieving the multidisciplinary consensus necessary to implement such changes. Despite these challenges, and with an existing body of evidence supporting its benefits, preoperative carbohydrate loading presents a significant contribution to the ERAS programs.


Subject(s)
Diet, Carbohydrate Loading/methods , Enhanced Recovery After Surgery , Preoperative Period , Dietary Carbohydrates/administration & dosage , Fasting , Humans , Insulin Resistance , Length of Stay , Models, Theoretical , Postoperative Care , Postoperative Complications/prevention & control , Practice Guidelines as Topic , Preoperative Care , Surgical Procedures, Operative/methods
14.
J Robot Surg ; 13(1): 35-40, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30047103

ABSTRACT

With the increasing popularity, frequency, and acceptance of the robotic-assisted laparoscopic radical prostatectomy procedure, an awareness of unique intra- and postoperative complications is heightened, including that of increases in intraocular pressure. The steep Trendelenburg positioning required for operative exposure has been shown to increase this value. While the literature is infrequent and undeveloped, certain anesthetic parameters including deep neuromuscular blockade, modified positioning, and the use of dexmedetomidine have been shown to have mild-to-modest decreases in intraocular pressure for baseline. In the four randomized control trials and four observational studies that were found via PubMed/Medline search, the aforementioned techniques demonstrate some preliminary evidence of operative considerations in this unique patient population. These modifications may prove to have even greater significance in patients with pre-existing ophthalmologic pathologies, such as glaucoma, which were excluded from the studies' analyses. This review summarizes the early literature obtained in this subject, with the intent of emphasizing the initial hypotheses and identifying areas for future study.


Subject(s)
Head-Down Tilt/physiology , Intraocular Pressure , Intraoperative Complications/etiology , Laparoscopy/methods , Ocular Hypertension/etiology , Ocular Hypertension/physiopathology , Postoperative Complications/etiology , Prostatectomy/methods , Robotic Surgical Procedures/methods , Aged , Anesthesia , Anesthetics , Databases, Bibliographic , Dexmedetomidine , Humans , Intraoperative Complications/prevention & control , Male , Middle Aged , Neuromuscular Blockade , Ocular Hypertension/prevention & control , Postoperative Complications/prevention & control
15.
A A Pract ; 10(10): 265-266, 2018 May 15.
Article in English | MEDLINE | ID: mdl-29757796

ABSTRACT

High dose rate interstitial brachytherapy is a commonly performed procedure for carcinoma of the lower lip. Placement of the brachytherapy catheters can be painful and may require monitored anesthesia care or general anesthesia. We present the use of bilateral mental nerve blocks with minimal sedation to facilitate placement of brachytherapy catheters.

SELECTION OF CITATIONS
SEARCH DETAIL